Literature DB >> 24307605

Development and comparison of new high-efficiency dry powder inhalers for carrier-free formulations.

Srinivas R B Behara1, P Worth Longest, Dale R Farkas, Michael Hindle.   

Abstract

High-efficiency dry powder inhalers (DPIs) were developed and tested for use with carrier-free formulations across a range of different inhalation flow rates. Performance of a previously reported DPI was compared with two new designs in terms of emitted dose (ED) and aerosolization characteristics using in vitro experiments. The two new designs oriented the capsule chamber (CC) at different angles to the main flow passage, which contained a three-dimensional (3D) rod array for aerosol deaggregation. Computational fluid dynamics simulations of a previously developed deaggregation parameter, the nondimensional specific dissipation (NDSD), were used to explain device performance. Orienting the CC at 90° to the mouthpiece, the CC90 -3D inhaler provided the best performance with an ED = 73.4%, fine particle fractions (FPFs) less than 5 and 1 μm of 95.1% and 31.4%, respectively, and a mass median aerodynamic diameter (MMAD) = 1.5 μm. For the carrier-free formulation, deaggregation was primarily influenced by capsule aperture position and the NDSD parameter. The new CC-3D inhalers reduced the percent difference in FPF and MMAD between low and high flows by 1-2 orders of magnitude compared with current commercial devices. In conclusion, the new CC-3D inhalers produced extremely high-quality aerosols with little sensitivity to flow rate and are expected to deliver approximately 95% of the ED to the lungs.
© 2013 Wiley Periodicals, Inc. and the American Pharmacists Association.

Entities:  

Keywords:  3D rod array; PTFE coating; computational fluid dynamics (CFD); excipient enhanced growth (EEG) delivery; flow rate effects; high efficiency DPI; in vitro inhaler testing; multiple formulations; non-dimensional specific dissipation (NDSD); respiratory drug delivery

Mesh:

Substances:

Year:  2013        PMID: 24307605      PMCID: PMC3947484          DOI: 10.1002/jps.23775

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  39 in total

1.  Scintigraphic comparison of budesonide deposition from two dry powder inhalers.

Authors:  S P Newman; G R Pitcairn; P H Hirst; R E Bacon; E O'Keefe; M Reiners; R Hermann
Journal:  Eur Respir J       Date:  2000-07       Impact factor: 16.671

2.  Influence of size and surface roughness of large lactose carrier particles in dry powder inhaler formulations.

Authors:  Martin J Donovan; Hugh D C Smyth
Journal:  Int J Pharm       Date:  2010-09-15       Impact factor: 5.875

3.  Evaluation of the Respimat Soft Mist Inhaler using a concurrent CFD and in vitro approach.

Authors:  P Worth Longest; Michael Hindle
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2009-06       Impact factor: 2.849

Review 4.  Issues in the use of inhaled glucocorticoids. The Asthma Clinical Research Network.

Authors:  A K Kamada; S J Szefler; R J Martin; H A Boushey; V M Chinchilli; J M Drazen; J E Fish; E Israel; S C Lazarus; R F Lemanske
Journal:  Am J Respir Crit Care Med       Date:  1996-06       Impact factor: 21.405

5.  Targeting aerosol deposition to and within the lung airways using excipient enhanced growth.

Authors:  Geng Tian; P Worth Longest; Xiang Li; Michael Hindle
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2013-01-03       Impact factor: 2.849

6.  Performance of combination drug and hygroscopic excipient submicrometer particles from a softmist inhaler in a characteristic model of the airways.

Authors:  P Worth Longest; Geng Tian; Xiang Li; Yoen-Ju Son; Michael Hindle
Journal:  Ann Biomed Eng       Date:  2012-07-21       Impact factor: 3.934

7.  Degree of throat deposition can explain the variability in lung deposition of inhaled drugs.

Authors:  Lars Borgström; Bo Olsson; Lars Thorsson
Journal:  J Aerosol Med       Date:  2006

8.  Aerosolization characteristics of dry powder inhaler formulations for the excipient enhanced growth (EEG) application: effect of spray drying process conditions on aerosol performance.

Authors:  Yoen-Ju Son; P Worth Longest; Michael Hindle
Journal:  Int J Pharm       Date:  2013-01-10       Impact factor: 5.875

9.  Condensational growth of combination drug-excipient submicrometer particles for targeted high-efficiency pulmonary delivery: evaluation of formulation and delivery device.

Authors:  Michael Hindle; P Worth Longest
Journal:  J Pharm Pharmacol       Date:  2012-02-21       Impact factor: 3.765

Review 10.  Inhalation adjuvant therapy for lung cancer.

Authors:  Dandan Yi; Timothy Scott Wiedmann
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2010-08       Impact factor: 2.849

View more
  13 in total

1.  Use of Computational Fluid Dynamics (CFD) Dispersion Parameters in the Development of a New DPI Actuated with Low Air Volumes.

Authors:  Worth Longest; Dale Farkas; Karl Bass; Michael Hindle
Journal:  Pharm Res       Date:  2019-05-28       Impact factor: 4.200

2.  Understanding the Impacts of Surface Compositions on the In-Vitro Dissolution and Aerosolization of Co-Spray-Dried Composite Powder Formulations for Inhalation.

Authors:  Sharad Mangal; Rongkun Xu; Heejun Park; Dmitry Zemlyanov; Nivedita Shetty; Yu-Wei Lin; David Morton; Hak-Kim Chan; Jian Li; Qi Tony Zhou
Journal:  Pharm Res       Date:  2018-11-07       Impact factor: 4.200

3.  Development of high efficiency ventilation bag actuated dry powder inhalers.

Authors:  Srinivas R B Behara; P Worth Longest; Dale R Farkas; Michael Hindle
Journal:  Int J Pharm       Date:  2014-02-07       Impact factor: 5.875

4.  Efficient Nose-to-Lung (N2L) Aerosol Delivery with a Dry Powder Inhaler.

Authors:  P Worth Longest; Laleh Golshahi; Srinivas R B Behara; Geng Tian; Dale R Farkas; Michael Hindle
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2014-09-05       Impact factor: 2.849

5.  The acoustic features of inhalation can be used to quantify aerosol delivery from a Diskus™ dry powder inhaler.

Authors:  Jansen N Seheult; Peter O'Connell; Kee Chun Tee; Tariq Bholah; Hasan Al Bannai; Imran Sulaiman; Elaine MacHale; Shona D'Arcy; Martin S Holmes; David Bergin; Emer Reeves; Richard B Reilly; Gloria Crispino-O'Connell; Carsten Ehrhardt; Anne Marie Healy; Richard W Costello
Journal:  Pharm Res       Date:  2014-05-28       Impact factor: 4.200

6.  Efficient Nose-to-Lung Aerosol Delivery with an Inline DPI Requiring Low Actuation Air Volume.

Authors:  Dale Farkas; Michael Hindle; P Worth Longest
Journal:  Pharm Res       Date:  2018-08-21       Impact factor: 4.200

7.  Validating Whole-Airway CFD Predictions of DPI Aerosol Deposition at Multiple Flow Rates.

Authors:  P Worth Longest; Geng Tian; Navvab Khajeh-Hosseini-Dalasm; Michael Hindle
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2016-04-15       Impact factor: 2.849

Review 8.  Use of computational fluid dynamics deposition modeling in respiratory drug delivery.

Authors:  P Worth Longest; Karl Bass; Rabijit Dutta; Vijaya Rani; Morgan L Thomas; Ahmad El-Achwah; Michael Hindle
Journal:  Expert Opin Drug Deliv       Date:  2018-12-10       Impact factor: 6.648

9.  Characterization of a New High-Dose Dry Powder Inhaler (DPI) Based on a Fluidized Bed Design.

Authors:  Dale R Farkas; Michael Hindle; P Worth Longest
Journal:  Ann Biomed Eng       Date:  2015-05-19       Impact factor: 3.934

10.  Development of an Inline Dry Powder Inhaler That Requires Low Air Volume.

Authors:  Dale Farkas; Michael Hindle; P Worth Longest
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2017-12-20       Impact factor: 2.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.